ABBV · News · 20260804N

Outstanding Indebtedness

AbbVie Inc. · 2026-08-04 · Importance 64 · Surprise 42 · In source text

AbbVie launched a $10 billion bond sale to finance its pending Apogee Therapeutics acquisition. Earlier reporting indicated the company was seeking to raise at least $8 billion in debt for the transaction. The debt financing will increase leverage to fund the approximately $10.9 billion acquisition.

Key facts

Impact estimates

metricdirectionstageexpectedbasis
liabilitynegativeprobableAbbVie Inc. has initiated a $10 billion bond sale to finance its acquisition of Apogee Therapeutics.